🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Ivan Borrello

Tampa General Hospital

ORCID: 0000-0002-7316-8862
MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 10 papers. Top paper: “Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide”.

Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide

Blood Advances(2020)10.1182/bloodadvances.2020001729
N/A
5.5DataRank · unranked
149 citations

Marianna Zahurak, Heather J. Symons, Kenneth R. Cooke, Gary L. Rosner, Douglas E. Gladstone +12 more

Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults

Blood Advances(2020)10.1182/bloodadvances.2020001648
N/A
3.1DataRank · unranked
74 citations

Marianna Zahurak, Yilin Cao, Allen Chen, Kenneth R. Cooke, Christopher Gamper +16 more

Thrombotic Microangiopathy after Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis

Biology of Blood and Marrow Transplantation(2020)10.1016/j.bbmt.2020.09.018
N/A
0DataRank · unranked
11 citations

Hua-Ling Tsai, Amy E. DeZern, Kevin Jerde, Lode J. Swinnen, Javier Bolaños‐Meade +13 more

Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide

Blood Advances(2020)10.1182/bloodadvances.2020002945
N/A
0DataRank · unranked
31 citations

Leo Luznik, Hua-Ling Tsai, Philip Imus, Amy E. DeZern, Keith W. Pratz +21 more

Impact of CD38 knockout in NK cells on daratumumab-mediated cytotoxicity and cellular metabolism.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e15018
N/A
0DataRank · unranked
0 citations

Meisam Naeimi Kararoudi, Syed Abbas Ali, Philip Imus, Marcelo de Souza Fernandes Pereira, Ezgi Elmas +4 more

A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML

Leukemia Research(2021)10.1016/j.leukres.2021.106737
N/A
0DataRank · unranked
8 citations

Tara M. Robinson, Amanda L. Blackford, Erica D. Warlick, Anna Ferguson, Ivan Borrello +4 more

Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience

Clinical Lymphoma Myeloma & Leukemia(2021)10.1016/j.clml.2021.09.022
N/A
0DataRank · unranked
6 citations

Matthew L. Smith, Hua‐Ling Tsai, Ravi Varadhan, Amy E. DeZern, W. Brian Dalton +23 more

Post-Transplantation Cyclophosphamide-Based Graft- versus-Host Disease Prophylaxis with Nonmyeloablative Conditioning for Blood or Marrow Transplantation for Myelofibrosis

Transplantation and Cellular Therapy(2022)10.1016/j.jtct.2022.02.004
N/A
0DataRank · unranked
27 citations

Hua‐Ling Tsai, Amy E. DeZern, Lukasz P. Gondek, Hany Elmariah, Javier Bolaños‐Meade +22 more

Allogeneic Blood or Marrow Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Age ≥55 Years

Transplantation and Cellular Therapy(2022)10.1016/j.jtct.2022.12.018
N/A
0DataRank · unranked
7 citations

Madison Reed, Hua‐Ling Tsai, Alexander J. Ambinder, Tania Jain, Amy E. DeZern +25 more

CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity

Blood(2020)10.1182/blood.2020006200
N/A
0DataRank · unranked
128 citations

Yuya Nagai, Ezgi Elmas, Marcelo de Souza Fernandes Pereira, Syed Abbas Ali, Philip Imus +5 more